IP Verse

Cell Culture Compositions And Methods For Polypeptide Production - EP2841561

The patent EP2841561 was granted to F Hoffmann LA Roche on Jan 16, 2019. The application was originally filed on Apr 24, 2013 under application number EP13720203A. The patent is currently recorded with a legal status of "Revoked".

EP2841561

F HOFFMANN LA ROCHE
Application Number
EP13720203A
Filing Date
Apr 24, 2013
Status
Revoked
May 15, 2024
Publication Date
Jan 16, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BREUEROct 16, 2019BREUERADMISSIBLE
GRUNECKER PATENT UND RECHTSANWALTE PARTG MBBOct 16, 2019-ADMISSIBLE

Patent Citations (47) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0117058
DESCRIPTIONEP0117060
DESCRIPTIONEP0307247
DESCRIPTIONEP0404097
DESCRIPTIONUS2003087372
DESCRIPTIONUS2005260186
DESCRIPTIONUS2006104968
DESCRIPTIONUS2011039330
DESCRIPTIONUS4399216
DESCRIPTIONUS4560655
DESCRIPTIONUS4657866
DESCRIPTIONUS4767704
DESCRIPTIONUS4816567
DESCRIPTIONUS4927762
DESCRIPTIONUS5091178
DESCRIPTIONUS5122469
DESCRIPTIONUS5691202
DESCRIPTIONUS6048728
DESCRIPTIONUS6171586
DESCRIPTIONUS6180401
DESCRIPTIONUS6267958
DESCRIPTIONUS6900056
DESCRIPTIONUS7601535
DESCRIPTIONUSRE30985E
DESCRIPTIONWO2006044908
DESCRIPTIONWO8700195
DESCRIPTIONWO9003430
DESCRIPTIONWO9108291
DESCRIPTIONWO9311161
EXAMINATIONEP0591605
INTERNATIONAL-SEARCH-REPORTWO2006026445
INTERNATIONAL-SEARCH-REPORTWO2006050050
INTERNATIONAL-SEARCH-REPORTWO2009014272
INTERNATIONAL-SEARCH-REPORTWO2009129379
INTERNATIONAL-SEARCH-REPORTWO2010036767
INTERNATIONAL-SEARCH-REPORTWO9815614
OPPOSITIONEP0076647
OPPOSITIONEP0591605
OPPOSITIONUS2004142382
OPPOSITIONUS2006051347
OPPOSITIONUS4816401
OPPOSITIONWO02066603
OPPOSITIONWO2006026445
OPPOSITIONWO2006050050
OPPOSITIONWO2008071394
OPPOSITIONWO2011134920
OPPOSITIONWO9815614

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- BURGENER et al., "Chapter 3 - Medium Development", BURGENER et al., Sadettin S. Ozturk, Wei-Show Hu, CELL CULTURE TECHNOLOGY FOR PHARMACEUTICAL AND CELL -BASED THERAPIES, CRC Press, (20060000), pages 5pp, 41 - 79, XP055454641
OPPOSITION- "Degree of coloration of liquids", European Pharmacopoeia, (20080000), pages 22 - 24, XP055652747
OPPOSITION- EMEA GUIDELINE, "ICH Topic MQ4 - Common technical document for the registration of pharmaceuticals for human use - quality", CPMP/ICH/2887/99 - Quality, pages 1 - 6 ; 20, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-4-g-common-technical-document-registration-pharmaceuticals-human-use-quality-step-5_en.pdf, XP055652753
OPPOSITION- EMEA GUIDELINE, "ICH Topic Q 6 A - Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances", CPMP/ICH/367/96, (200005), pages 1 - 2, 8-9, URL: https://www.ema.europa.eu/en/documents/scientific-qu deline/ich-q-6-test-procedures- acceptance-criteria-new-driiq-substances-new-druq-products-chemicai en.pdf ., XP055652754
OPPOSITION- ETO et al., "Development of a Protein-free Medium with Ferric Citrate Substituting Transferrin for the Cultivation of Mouse-Mouse Hybridomas", Agricult. Biol. Chem., (19910000), vol. 55, no. 3, pages 863 - 865, XP009037169
OPPOSITION- NAGIRA et al., "Development of a Protein-free Medium with Iron Salts Replacing Transferrin for a Human-Human Hybridoma", Biosci. Biotech. Biochem., (19950000), vol. 59, no. 4, pages 743 - 745, XP009027924
OPPOSITION- NISHIUCH et al., "Cytotoxicity of Cystein in Culture Media", In Vitro, (19760000), vol. 12, no. 9, pages 635 - 638, XP055453044
OPPOSITION- HARRIS et al., "Commercial Manufacturing Scale Formulation and Analytical Characterization of Therapeutic Recombinant Antibodies", Drug Development Research, (20040000), vol. 61, pages 137 - 154, XP002649544
OPPOSITION- WANG W. et al., "Antibody Structure, Instability, and Formulation", Journal of Pharmaceutical Sciences, (20070100), vol. 96, no. 1, pages 1 - 26, XP009084505
OPPOSITION- Ann L Daugherty and Randall J Mrsny, "Formulation and Delivery Issues for Monoclonal Antibody Therapeutics", Ann L Daugherty and Randall J Mrsny, Steven J Shire; Wayne Gombotz; Karoline Bechtold-Peters and James Andya, Current Trends in Monoclonal Antibody Development and Manufacturing,, Springer, US, (20100000), pages 103 - 129, XP009133774
OPPOSITION- KIM et al., "CHO cells in biotechnology for production of recombinant proteins: current state and further potential", Appl. Microbiol. Biotech, (20120000), vol. 93, pages 917 - 930, XP035006081
OPPOSITION- INNIS et al., "Variations in Riboflavin Binding by Human Plasma: identification of Immunoglobulins as the Major Proteins Responsible", Biochem. Med., (19850000), vol. 34, pages 151 - 165, XP026166164
OPPOSITION- DAUGHERTY et al., "Formulation and Delivery Issues for Monoclonal Antibody Therapeutics", Adv. Drug. Deliv. Rev., (20060000), vol. 58, pages 686 - 706, XP024892149
OPPOSITION- WARNE N., "Development of high concentration protein biopharmaceuticals:The use of platform approaches in formulation developmen", European Journal of Pharmaceutics and Biopharmaceutics, (20110303), vol. 78, no. 2, pages 208 - 212, XP028203394
OPPOSITION- JING et al., "Identification of cell culture conditions to control protein aggregation of IgG fusion proteins expressed in Chinese hamster ovary cells", Process Biochem., (20120000), vol. 47, pages 69 - 75, XP028342261
OPPOSITION- "Chapter 2: General Principles of Protein Fractionation", T. KAWAI, Clinical Aspects of The Plasma Proteins, Berlin Heidelberg, Springer, (19730000), pages 6 - 7, XP055090667
OPPOSITION- LIU et al., "Recovery and purification process development for monoclonal antibody production", mAbs, (20100000), vol. 2, no. 5, pages 480 - 499, XP055027612

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents